Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2012, Article ID 580306, 8 pages
Review Article

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

Received 16 November 2012; Accepted 18 December 2012

Academic Editor: J. W. Moul

Copyright © 2012 Matthew E. Johnson and Mark K. Buyyounouski. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Androgen deprivation therapy is commonly used in combination with radiotherapy as part of the definitive treatment for men with clinically localized and locally advanced prostate cancer. Androgen deprivation has been associated with a wide range of iatrogenic effects impacting a variety of body systems including metabolic, musculoskeletal, cardiovascular, neurocognitive, and sexual. This review aims to provide the radiation oncology community with the knowledge to monitor and manage androgen deprivation therapy toxicity in an effort to provide the highest level of care for patients and to minimize the iatrogenic effects of androgen deprivation as much as possible.